NYU Abu Dhabi Develops Biodegradable 3D-Printed Gastric Stent for Post-Surgery Treatment

This advancement in medical technology addresses a critical complication in bariatric surgery, potentially reducing healthcare costs and improving patient experiences.

• On August 26, 2026, NYU Abu Dhabi researchers unveiled the BRIDGE gastric stent, designed to treat gastric leaks post-bariatric surgery.
• The stent features a biodegradable design that enhances drainage performance by two-fold compared to conventional options.
• Currently in laboratory testing, the BRIDGE stent aims to eliminate the need for follow-up removal procedures, streamlining patient recovery.

• Gastric leaks are a common complication after bariatric surgery, often requiring additional procedures that can prolong recovery and increase healthcare costs.
• Traditional stents used for drainage can lead to complications such as migration and kinking, necessitating further interventions.
• Prior innovations, like the non-biodegradable Lily stent, have laid the groundwork for this new development, showcasing the potential for improved designs in medical devices.

The introduction of the BRIDGE gastric stent represents a significant leap in the treatment of gastric leaks, a complication that affects approximately 13.8% of bariatric surgery patients. This new device, developed by researchers at NYU Abu Dhabi, utilizes a triply periodic minimal surface (TPMS) lattice architecture, which is a sophisticated design that enhances fluid drainage. The stent is 3D-printed using biodegradable materials, allowing it to dissolve naturally after the healing process, thereby eliminating the need for surgical removal.

The BRIDGE stent's design is a response to the limitations of conventional stents, which often struggle with drainage efficiency and can cause additional complications. In laboratory tests, the BRIDGE stent demonstrated a two-fold increase in drainage performance and a 7.1-fold improvement in kink resistance, making it a promising alternative for patients facing gastric leaks. This innovation not only aims to improve patient outcomes but also seeks to reduce the burden on healthcare systems by minimizing the need for repeat procedures and extended hospital stays.

The collaboration between NYU Abu Dhabi and Cleveland Clinic Abu Dhabi highlights a growing trend in the UAE towards investing in biomedical innovation. As healthcare institutions in the region continue to prioritize research and development, the potential for locally developed medical technologies to enhance patient care becomes increasingly viable. However, it is important to note that the BRIDGE stent is still in the laboratory prototype stage, with further clinical studies required before it can be commercially available.

The implications of this development extend beyond immediate patient care. By improving the efficiency of post-surgical treatments, the BRIDGE stent could lead to lower healthcare costs and better resource allocation within hospitals. This is particularly relevant in the UAE, where the healthcare sector is rapidly evolving and adapting to meet the needs of a growing population.

• Bariatric surgery patients: They will benefit from reduced complications and improved recovery times.
• Healthcare providers: Hospitals may see decreased costs associated with repeat procedures and extended stays.
• Medical device manufacturers: Companies involved in stent production may need to adapt to new standards and technologies.
• Researchers and innovators: The success of this stent could inspire further advancements in biodegradable medical devices.

• Clinical trial results: The outcomes of upcoming clinical studies will determine the stent's effectiveness and safety in real-world applications.
• Regulatory approvals: Monitoring the timeline for regulatory reviews will indicate when the stent might become available to patients.
• Market adoption: Observing how quickly healthcare facilities integrate this technology into their practices will reveal its impact on patient care.